Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine

C. A. Presant, Alex Denes, L. Klein, S. Garrett, G. E. Metter

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

6-Thioguanine was administered iv or orally to 66 patients on an intermittent schedule, one dose every 3 weeks. Doses were gradually escalated until moderate toxicity was observed. The dose-limiting toxic effects were myelosuppression and azotemia. The recommended starting doses for phase II or III studies were 700 mg/m 2 iv and 1400 mg/m 2 orally. Nephrotoxicity and myelosuppression were reversible in all clearly drug-related instances. Myelosuppression was transient, with nadir blood cell counts observed 10-14 days after drug administration. No cumulative toxicity was observed. Antitumor responses were observed in five of 21 evaluable patients with metastatic colorectal carcinoma including two of four previously untreated patients with that disease. Other than a transient response in a patient with endometrial carcinoma, who received her drug orally, all other responses were observed in patients treated iv with 6-thioguanine. Further phase II trials, particularly in colorectal carcinoma, are recommended.

Original languageEnglish (US)
Pages (from-to)1109-1113
Number of pages5
JournalCancer Treatment Reports
Volume64
Issue number10-11
StatePublished - 1980
Externally publishedYes

Fingerprint

Thioguanine
Colorectal Neoplasms
Pharmaceutical Preparations
Azotemia
Blood Cell Count
Poisons
Endometrial Neoplasms
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Presant, C. A., Denes, A., Klein, L., Garrett, S., & Metter, G. E. (1980). Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine. Cancer Treatment Reports, 64(10-11), 1109-1113.

Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine. / Presant, C. A.; Denes, Alex; Klein, L.; Garrett, S.; Metter, G. E.

In: Cancer Treatment Reports, Vol. 64, No. 10-11, 1980, p. 1109-1113.

Research output: Contribution to journalArticle

Presant, CA, Denes, A, Klein, L, Garrett, S & Metter, GE 1980, 'Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine', Cancer Treatment Reports, vol. 64, no. 10-11, pp. 1109-1113.
Presant CA, Denes A, Klein L, Garrett S, Metter GE. Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine. Cancer Treatment Reports. 1980;64(10-11):1109-1113.
Presant, C. A. ; Denes, Alex ; Klein, L. ; Garrett, S. ; Metter, G. E. / Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine. In: Cancer Treatment Reports. 1980 ; Vol. 64, No. 10-11. pp. 1109-1113.
@article{7e5d1b2b2163445c80666ecec4bca9df,
title = "Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine",
abstract = "6-Thioguanine was administered iv or orally to 66 patients on an intermittent schedule, one dose every 3 weeks. Doses were gradually escalated until moderate toxicity was observed. The dose-limiting toxic effects were myelosuppression and azotemia. The recommended starting doses for phase II or III studies were 700 mg/m 2 iv and 1400 mg/m 2 orally. Nephrotoxicity and myelosuppression were reversible in all clearly drug-related instances. Myelosuppression was transient, with nadir blood cell counts observed 10-14 days after drug administration. No cumulative toxicity was observed. Antitumor responses were observed in five of 21 evaluable patients with metastatic colorectal carcinoma including two of four previously untreated patients with that disease. Other than a transient response in a patient with endometrial carcinoma, who received her drug orally, all other responses were observed in patients treated iv with 6-thioguanine. Further phase II trials, particularly in colorectal carcinoma, are recommended.",
author = "Presant, {C. A.} and Alex Denes and L. Klein and S. Garrett and Metter, {G. E.}",
year = "1980",
language = "English (US)",
volume = "64",
pages = "1109--1113",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10-11",

}

TY - JOUR

T1 - Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine

AU - Presant, C. A.

AU - Denes, Alex

AU - Klein, L.

AU - Garrett, S.

AU - Metter, G. E.

PY - 1980

Y1 - 1980

N2 - 6-Thioguanine was administered iv or orally to 66 patients on an intermittent schedule, one dose every 3 weeks. Doses were gradually escalated until moderate toxicity was observed. The dose-limiting toxic effects were myelosuppression and azotemia. The recommended starting doses for phase II or III studies were 700 mg/m 2 iv and 1400 mg/m 2 orally. Nephrotoxicity and myelosuppression were reversible in all clearly drug-related instances. Myelosuppression was transient, with nadir blood cell counts observed 10-14 days after drug administration. No cumulative toxicity was observed. Antitumor responses were observed in five of 21 evaluable patients with metastatic colorectal carcinoma including two of four previously untreated patients with that disease. Other than a transient response in a patient with endometrial carcinoma, who received her drug orally, all other responses were observed in patients treated iv with 6-thioguanine. Further phase II trials, particularly in colorectal carcinoma, are recommended.

AB - 6-Thioguanine was administered iv or orally to 66 patients on an intermittent schedule, one dose every 3 weeks. Doses were gradually escalated until moderate toxicity was observed. The dose-limiting toxic effects were myelosuppression and azotemia. The recommended starting doses for phase II or III studies were 700 mg/m 2 iv and 1400 mg/m 2 orally. Nephrotoxicity and myelosuppression were reversible in all clearly drug-related instances. Myelosuppression was transient, with nadir blood cell counts observed 10-14 days after drug administration. No cumulative toxicity was observed. Antitumor responses were observed in five of 21 evaluable patients with metastatic colorectal carcinoma including two of four previously untreated patients with that disease. Other than a transient response in a patient with endometrial carcinoma, who received her drug orally, all other responses were observed in patients treated iv with 6-thioguanine. Further phase II trials, particularly in colorectal carcinoma, are recommended.

UR - http://www.scopus.com/inward/record.url?scp=0019296179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019296179&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 1109

EP - 1113

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10-11

ER -